← All trials
NCT01813435
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2013
- Primary completion
- Dec 1, 2017
- Completion date
- Dec 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 16000
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- ECRI bvLead sponsor
- University of BernOverall official - principal investigator
- University of ParisOverall official - principal investigator
- Hasselt UniversityOverall official - principal investigator
- University of TorontoOverall official - principal investigator
- AstraZenecaCollaborator
- The Medicines CompanyCollaborator
- Biosensors InternationalCollaborator
- Kerckoff clinic, Bad Nauheim, GermanyOverall official - principal investigator
- Erasmus University RotterdamStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.